Nanjing Military Command Fuzhou General Hospital

Fuzhou, China

Nanjing Military Command Fuzhou General Hospital

Fuzhou, China

Time filter

Source Type

Wang W.,Nanjing Military Command Fuzhou General Hospital | Ouyang X.,Nanjing Military Command Fuzhou General Hospital | Jiang H.,Nanhua University
Chinese-German Journal of Clinical Oncology | Year: 2010

Objective: The aim of our study was to investigate the relationship between cell apoptosis and dephosphorylated RB protein and proliferating cell nuclear antigen (PCNA) in human breast cancer. Methods: MTT colorimetric assay was applied to examine the growth inhibition, and the apoptosis was determined by flow cytometry (FCM). The expressing quantity of dephosphorylated RB protein and PCNA pre- and post the action of ADR were detected with immunocytochemistry. Results: MTT assay revealed that ADR inhibited proliferation of MCF-7/S cells in a dose dependent manner, the 50% inhibition concentration (IC50) value was 0.128 mg/L. Tumor cell apoptotic rate (AR) in ADR group (x= 0.259) was significantly higher than that in the control group (x = 0.045) (P < 0.01). The expressive levels of dephosphorylated RB protein in ADR group (MOD × area = 986.8 ± 207.4) was significantly higher than that in control group (MOD × area =131.7 ± 31.9) (P < 0.01). PCNA positive expression rate in ADR group (x = 0.3371) was significantly lower than that in the control group (x = 0.5152) (P < 0.01). Conclusion: In ADR group, there was significant positive correlation between AR and the expressing quantity of dephosphorylated RB protein, but there was significant negative correlation between AR and PCNA . © Springer-Verlag Berlin Heidelberg 2010.


Wang W.,Nanjing Military Command Fuzhou General Hospital | Ou-Yang X.,Nanjing Military Command Fuzhou General Hospital | Chen X.,Nanjing Military Command Fuzhou General Hospital | Yu Z.,Nanjing Military Command Fuzhou General Hospital
Chinese-German Journal of Clinical Oncology | Year: 2013

Objective: The aim of our study was to evaluate the toxicity and efficacy of induction chemotherapy (ICT) followed by three-dimensional conformal radiotherapy (3D CRT) and concurrent weekly paclitaxel on unresectable non-small cell lung cancer (NSCLC). Methods: Stage III NSCLC patients with favorable conditions were treated with 2 to 4 cycles of carboplatin (AUC = 5-6, d1) combined with paclitaxel (175 mg/m2, d1), then followed by weekly paclitaxel (40 mg/m2) and concurrent 3D CRT within 3-4 weeks. The prescription dose was given as high as possible under the condition that V20 ≤ 31% and spinal cord dose ≤ 50 Gy. Results: Thirty-one patients were enrolled. ICT was well tolerated. During the concurrent chemoradiotherapy, the treatment of 3 patients was ended ahead of the schedule because of severe pulmonary and heart toxicities; the treatment of 2 patients was delayed for 7 and 12 days because of fatigue. Myelosuppression was mild (16/31): all were grade 1-2 except 1 was grade 3. Lymphocytopenia was more obvious (29/31, grade 3 in 21). Three patients developed grade 3 radiation-induced esophagitis, and 2 developed grades 3-4 radiation-induced pneumonitis. Two developed grade 3 esophageal stricture. No grades 3-4 pulmonary fibrosis was observed. The overall response rate was 74.1%. The 1-, 2-, 3-year overall survival rates were 74.2%, 41.9%, and 34.6%, respectively, with the median survival time of 18.5 months. The 1-, 2-, 3-year local progression-freely survival rates were 64.5%, 32.3%, and 20.5%, respectively, with the median local progression-freely survival time of 14.3 months. Conclusion: The program of ICT followed by weekly paclitaxel and 3D CRT is accomplished in most of the favorable stage III NSCLC patients. The toxicity is tolerable, and the response rate is inspiriting. © 2013 Springer-Verlag Berlin Heidelberg.


Lin C.,Nanjing Military Command Fuzhou General Hospital | Chen X.,Nanjing Military Command Fuzhou General Hospital | Liu J.,Nanjing Military Command Fuzhou General Hospital | Huang Y.,Nanjing Military Command Fuzhou General Hospital | Ou-Yang X.,Nanjing Military Command Fuzhou General Hospital
Chinese Journal of Lung Cancer | Year: 2014

Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get benefit from them. Immunotherapy, through stimulating the body's immune system to improve the antitumor immunity effect, has been a new therapeutic method for non-small cell lung cancer (NSCLC). Study had been reported that immune checkpoint molecules, including programmed death-1 (PD-1)/PD-ligand (L) 1 axis, are closedly related with cancer generation and development, and play a key role on clinical significance of NSCLC. Activation of PD-1/PD-L1 pathway contributes to tumor immune escape, and block PD-1/PD-L1 pathway can enhance endogenous antimuor immunity. Currently increasing clinical trials suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies turned out to be beneficial and safe in NSCLC. Here, we provide a review on the progress of PD-1/PD-L1 pathway and immune checkpoint inhibitors in NSCLC. © 2014 Chinese Journal of Lung Cancer. All rights reserved.


PubMed | NanJing Military Command Fuzhou General Hospital
Type: Journal Article | Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer | Year: 2010

Lentinus edodes polysaccharide (Lentinan) has attracted great attention from both pharmacologists and clinicians as a biological response modifier, and is widely used as an anti-tumor agent in both China and Japan. The aim of this study is to observe the efficacy of Lentinan combined with chemotherapy in stage III-IV non-small cell lung cancer (NSCLC).Eighty-one patients with stage III-IV NSCLC were randomly divided into two groups: (1)Lentinan + chemotherapy group (group A, 42 cases); (2)Simple chemotherapy group (group B, 39 cases). The peripheral blood T lymphocyte subsets (CD3, CD4, CD4/CD8) and natural killer (NK) cell activity of patients in both groups were measured before and after treatment, while compared with healthy control (30 cases). The immune functions, the effect of treatment, quality of life, and adverse reactions were observed.After treatment the objective response rate (CR+PR) was 50% in group A, compared to 33% in group B (P < 0.05). The blood T cell levels(CD3, CD4, CD4/CD8) and NK cell activity in group A increased (P < 0.01), CD8 reduced (P < 0.05), but in group B the value had no obvious change (P > 0.05). Quality of life in group A was higher than that in group B (P < 0.01). The incidence of grade II-IV leukopenia, nausea and vomiting in group B was much higher than those in group A (P < 0.05).The therapeutic effect of Lentinan combined with chemotherapy is better than that of chemotherapy alone.


PubMed | Nanjing Military Command Fuzhou General Hospital
Type: Journal Article | Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer | Year: 2014

Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get benefit from them. Immunotherapy, through stimulating the bodys immune system to improve the antitumor immunity effect, has been a new therapeutic method for non-small cell lung cancer (NSCLC). Study had been reported that immune checkpoint molecules, including programmed death-1 (PD-1)/PD-ligand (L) 1 axis, are closedly related with cancer generation and development, and play a key role on clinical significance of NSCLC. Activation of PD-1/PD-L1 pathway contributes to tumor immune escape, and block PD-1/PD-L1 pathway can enhance endogenous antimuor immunity. Currently increasing clinical trials suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies turned out to be beneficial and safe in NSCLC. Here, we provide a review on the progress of PD-1/PD-L1 pathway and immune checkpoint inhibitors in NSCLC.


PubMed | Nanjing Military Command Fuzhou General Hospital
Type: Journal Article | Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer | Year: 2010

The main treatment strategy of cancer patients with brain meta- stasis is irradiation, while so far there is few research concerning chemotherapy combined with radiotherapy for these patients. The aim of this study is to evaluate the therapeutic effect and toxicity of chemotherapy with VPC regimen combined with whole-brain radiotherapy (WBRT) in small cell lung cancer (SCLC) with brain metastasis.A total of 60 SCLC patients with brain metastasis received a cycle of VPC regimen (teniposide 60mg/m iv on days 1-5, cisplatin 35mg/m iv on days 1-3, semustine 80mg/m PO on day 1) every 3-4 weeks. WBRT was administered on day 6 of the first cycle of chemotherapy at a dose of 2Gy given in 5 fractions per week. Patients with less than 3 brain lesions received WBRT at a dose of 30Gy and then small field radiotherapy up to total dose of 50Gy, otherwise they received WBRT at a total dose of 40Gy. Response was evaluated by brain and chest CT or MRI after WBRT and at least 2 cycles of chemotherapy were completed.All the patients completed WBRT combined with chemotherapy. Total response rate of primary pulmonary tumor was 46.7%, with 4 cases of CR. The objective brain response rate was 60.0%, with 11 cases of CR and 25 cases of PR. Symptom relief was observed in all 48 patients with neurological symptoms. Main adverse effects were myelotoxicity, nausea/vomiting, constipation and alopecia. The follow-up rate was 93.3% with a median survival duration of 11.3 months. The 1-, 2- and 5-year survival rate was 43.3%, 35.0% and 6.7%, respectively.Chemotherapy combined with WBRT can be safely performed for SCLC with brain metastasis and its short-term response is quite satisfactory. It may be worthy of further clinical investigation.

Loading Nanjing Military Command Fuzhou General Hospital collaborators
Loading Nanjing Military Command Fuzhou General Hospital collaborators